Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

586
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
586
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

415
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
415
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An international collaborative study to compare different von Willebrand factor glycoprotein Ib binding activity assays: the COMPASS-VWF study.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism.

Thrombosis research·2015
Same author

Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome.

Journal of thrombosis and haemostasis : JTH·2014
Same author

Comparative sensitivity of commonly used thromboplastins to ex vivo therapeutic rivaroxaban levels.

Thrombosis and haemostasis·2014
Same author

The automation of routine light transmission platelet aggregation.

International journal of laboratory hematology·2013
Same author

A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen.

Haemophilia : the official journal of the World Federation of Hemophilia·2013
Same journal

Male Range of Motion Norms in the Haemophilia Joint Health Score Underrepresent the Severity of Joint Damage in Females.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Physical Activity and Sedentary Behaviour in Children With Haemophilia.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Ten-year Demographic and Clinical Characterisation of People With Haemophilia: The Colombian Registry Experience.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Exploratory Claims-Based Assessment of Diagnosed and Potentially Undiagnosed von Willebrand Disease in Japan.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Use of an Oral Health-Related Quality of Life Instrument to Measure Unmet Dental Care Needs in Adults With Inherited Bleeding Disorders.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Clinical Factors for Predicting Synovial Hypertrophy in Early Haemophilic Arthropathy on Prophylaxis: A Cross-Sectional Study of Patient- and Joint-Level Analyses Using Musculoskeletal Ultrasound.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
See all related articles

Related Experiment Video

Updated: May 4, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.9K

Changes in factor XIII level during pregnancy.

L T Sharief1, A S Lawrie, I J Mackie

  • 1Institute of Women's Health, University College London, London, UK; Obstetrics and Gynaecology Department, Haemophilia centre and Thrombosis Unit, Royal Free Hospital NHS Foundation Trust, London, UK.

Haemophilia : the Official Journal of the World Federation of Hemophilia
|December 17, 2013
PubMed
Summary
This summary is machine-generated.

Pregnancy significantly reduces factor XIII (FXIII) activity, with levels decreasing throughout gestation. This study establishes new reference ranges for FXIII during pregnancy and postpartum, crucial for understanding haemostatic changes.

Keywords:
factor XIIIpostnatalpregnancytrimester

More Related Videos

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
08:45

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

Published on: May 10, 2022

1.8K
Assessment of Maternal Vascular Remodeling During Pregnancy in the Mouse Uterus
06:55

Assessment of Maternal Vascular Remodeling During Pregnancy in the Mouse Uterus

Published on: December 5, 2015

15.1K

Related Experiment Videos

Last Updated: May 4, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.9K
Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
08:45

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

Published on: May 10, 2022

1.8K
Assessment of Maternal Vascular Remodeling During Pregnancy in the Mouse Uterus
06:55

Assessment of Maternal Vascular Remodeling During Pregnancy in the Mouse Uterus

Published on: December 5, 2015

15.1K

Area of Science:

  • Obstetrics and Gynecology
  • Hematology
  • Clinical Chemistry

Background:

  • Pregnancy induces significant haemostatic alterations, including rising clotting factors.
  • Limited data exists on factor XIII (FXIII) level changes during pregnancy.

Purpose of the Study:

  • To assess changes in plasma FXIII activity throughout normal pregnancy.
  • To establish trimester-specific and immediate postnatal reference ranges for FXIII activity.

Main Methods:

  • Cross-sectional study of 376 women with normal pregnancies.
  • Plasma FXIII activity measured using a chromogenic assay on a CS-5100 analyser.
  • Samples collected during the first, second, third trimesters, and immediate postnatal period, with a non-pregnant control group.

Main Results:

  • Mean FXIII activity decreased progressively: first trimester (112 IU dL(-1)), second (96 IU dL(-1)), third (83 IU dL(-1)), and postnatal (90 IU dL(-1)).
  • Significant reduction in mean FXIII activity observed in the second and third trimesters compared to the first trimester and controls (P < 0.0001).
  • Postnatal FXIII levels were lower than the first trimester and control group.

Conclusions:

  • This study provides essential reference ranges for FXIII activity during pregnancy and the early postpartum period.
  • Normal pregnancy is associated with a significant decrease in FXIII activity, particularly in later trimesters.